Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$76.35 USD

76.35
673

+0.24 (0.32%)

Updated Aug 6, 2025 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit

by Zacks Equity Research

This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.

Zacks Equity Research

AMN Healthcare (AMN) Closes Advanced Medical Acquisition

by Zacks Equity Research

AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.

Zacks Equity Research

Agios (AGIO) Catches Eye: Stock Jumps 5.4%

by Zacks Equity Research

Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Here's Why You Should Hold on to PRA Health (PRAH) Stock Now

by Zacks Equity Research

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.

Zacks Equity Research

Will Haemonetics Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Haemonetics.

Trina Mukherjee headshot

Medical Products Industry Outlook: Growth Prospects Radiant

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Zacks Equity Research

Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.

Zacks Equity Research

Ecolab Unveils Innovative Tested Tool to Improve Food Safety

by Zacks Equity Research

Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.

Zacks Equity Research

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare (NXGN) Stock

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

Why Is Haemonetics (HAE) Up 7% Since Last Earnings Report?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Invest in DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.

Zacks Equity Research

Here's Why You Should Hold on to Medidata (MDSO) Stock Now

by Zacks Equity Research

Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.

Zacks Equity Research

3 Reasons Growth Investors Will Love Haemonetics (HAE)

by Zacks Equity Research

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Here's Why You Should Bet on Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.

Zacks Equity Research

Here's Why You Should Consider Betting On CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.

Zacks Equity Research

ABIOMED Gets FDA Confirmation of the Safety of Impella RP

by Zacks Equity Research

ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

Zacks Equity Research

Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.

Zacks Equity Research

3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

by Zacks Equity Research

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

by Zacks Equity Research

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Zacks Equity Research

Haemonetics (HAE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 10.91% and -0.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?